Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance

J Gastroenterol Hepatol. 2012 Apr;27(4):823-31. doi: 10.1111/j.1440-1746.2011.06882.x.

Abstract

Background and aim: The immunological mechanism by which ribavirin (RBV) polarizes the T-helper (Th) 1/2 balance toward Th1 predominancy is not fully understood. We therefore examined whether RBV affects costimulatory signaling, which is known to be essential for regulating the Th1/2 balance.

Methods: The expression of costimulatory molecules and their ligands, and levels of various cytokines, released from CD4(+) T cells obtained from healthy individuals or patients with chronic hepatitis C virus (HCV) infection were analyzed.

Results: In CD4(+) T cells, RBV selectively downmodulates the expression of inducible costimulator (ICOS), a ligand for B7-H2 on dendritic cells, which mainly differentiates Th0 into Th2 cells. Moreover, the levels of interleukin-10 (IL-10) released from RBV-stimulated CD4(+) T cells also decreased, indicating that the downmodulation of ICOS induced by RBV might be correlated with the decrease in IL-10 released from Th cells, leading to the inhibition of Th2 activity. An analysis of the association between ICOS kinetics and hepatitis C virus (HCV) elimination in hepatitis C patients receiving combined pegylated interferon and RBV indicated that HCV elimination tended to occur more frequently in patients showing ICOS downmodulation with RBV treatment. A decrease in IL-10 production by CD4(+) T cells was also observed in association with ICOS downregulation in patients who succeeded in HCV elimination.

Conclusions: The downmodulation of ICOS in correlation with a reduction in IL-10 produced by CD4(+) T cells is possibly the immunological mechanism of action of RBV, which polarizes the Th1/2 balance toward a Th1 cytokine profile, thus contributing to the elimination of cells chronically infected with HCV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism*
  • Cells, Cultured
  • Dendritic Cells / metabolism
  • Down-Regulation
  • Female
  • Hepacivirus
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / immunology
  • Humans
  • Inducible T-Cell Co-Stimulator Ligand / drug effects
  • Inducible T-Cell Co-Stimulator Ligand / metabolism*
  • Inducible T-Cell Co-Stimulator Protein / drug effects
  • Inducible T-Cell Co-Stimulator Protein / metabolism*
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Interferon-gamma / metabolism
  • Interleukin-10 / metabolism*
  • Interleukin-4 / metabolism
  • Male
  • Middle Aged
  • Polyethylene Glycols / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Ribavirin / pharmacology*
  • Signal Transduction
  • Viral Load

Substances

  • Antiviral Agents
  • Inducible T-Cell Co-Stimulator Ligand
  • Inducible T-Cell Co-Stimulator Protein
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Interleukin-10
  • Interleukin-4
  • Polyethylene Glycols
  • Ribavirin
  • Interferon-gamma
  • peginterferon alfa-2b